VYNE Therapeutics Inc.

VYNE Therapeutics Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immune-mediated diseases. Its pipeline has centered on small-molecule BET inhibitor programs, including VYN202 and repibresib, with development activities aimed at dermatology and other immune-mediated indications.

12.53

12.11

— VYNE Therapeutics Inc.
	%
Clinical-stage drug candidates	95% Small-molecule BET inhibitor programs being developed for immune-mediated conditions.
Royalty revenue	5% Royalties received under a licensing arrangement with LEO Pharma.

VYNE does not sell broadly to end consumers; its primary economic counterparties are pharmaceutical partners,...

Pharmaceutical partners and licenseesprimary
Buy or license development/commercial rights to pipeline assets and royalty-bearing programs.
Regulators and clinical trial ecosystemprimary
Support clinical advancement through trial oversight, site operations, and approvals.
Physicians and specialistssecondary
Would prescribe approved therapies for psoriasis and other immune-mediated diseases.
Healthcare payorssecondary
Reimburse approved treatments and influence market access and uptake.
Patients with immune-mediated diseasesecondary
End users of therapies for inflammatory skin and immune conditions.

VYNE is headquartered in the United States and develops its programs primarily for the U.S...

•Headquartered in the United States
•Core development focus includes U.S. clinical and regulatory pathways
•License agreement includes U.S. and certain non-U.S. milestones
•Commercial rights are structured country-by-country under licensing terms
•Reported revenue is royalty-based rather than geography-diversified

VYNE’s strategy is to advance its BET inhibitor programs through clinical development and seek regulatory approval in...

Advance VYN202 in immune-mediated diseaseshort-term

Clinical proof-of-concept is central to validating the BET inhibitor platform and creating partnering value.

Monetize pipeline through partnershipsmedium-term

External partners can provide capital, development scale, and commercialization capabilities.

Preserve optionality through strategic reviewshort-term

Asset sales, mergers, or other transactions may unlock value if standalone development is constrained.

VYNE faces the core risks of clinical-stage drug development: trial failure, safety issues, regulatory delays, and the...

critical

Clinical development failure

Preclinical and clinical studies may not demonstrate sufficient safety or efficacy for approval.

Scope: VYN202 and repibresib
Materiality: high

high

Competitive pressure in immune-mediated disease

Large pharmaceutical companies already market and develop therapies in psoriasis and related indications.

Scope: Psoriasis and adjacent inflammatory markets
Materiality: high

high

Financing risk

Development programs require additional capital before any product revenue is realized.

Scope: Pipeline funding and operating runway
Materiality: high

high

Strategic transaction execution risk

A merger, partnership, or asset sale may not close or may not deliver expected value.

Scope: Corporate strategy and valuation
Materiality: high

high

Regulatory and safety risk

FDA holds, endpoint failures, or adverse events can delay or stop development.

Scope: Clinical trials and approval pathway
Materiality: high

Research and development expense timing

Affects operating loss comparability

License milestone obligations

Affects liabilities and cash flow

Royalty revenue recognition

Affects reported revenue and timing

Stock-based compensation

Affects G&A and diluted share metrics

VYNE Therapeutics Inc.

Clinical development failure

Competitive pressure in immune-mediated disease

Financing risk

Strategic transaction execution risk

Regulatory and safety risk

Dyne Therapeutics, Inc.

Vyome Holdings, Inc

UNITED THERAPEUTICS Corp

SOLENO THERAPEUTICS INC

TherapeuticsMD, Inc.

Vynleads, Inc.